Residency · Residency · Interventional Radiology

Bronchial Artery Embolization for Hemoptysis

Overview

Bronchial artery embolization (BAE) is the first-line treatment for massive and recurrent hemoptysis. Massive hemoptysis defined as >300-600 mL in 24 hours (or any amount causing hemodynamic instability or respiratory compromise). Bronchial arteries are the source in ~90% of hemoptysis cases. Non-bronchial systemic arterial supply (intercostal, internal mammary, phrenic) contributes in 5-10%. Mortality from untreated massive hemoptysis is 50-80% (primarily from asphyxiation, not exsanguination).

Bronchial Artery Anatomy

Normal Anatomy

Bronchial arteries arise from the descending thoracic aorta, typically at T5-T6 level. Right intercostobronchial trunk (ICBT): common origin of right bronchial artery and a right intercostal artery — most important vessel to identify. Left bronchial arteries typically arise directly from the anterior aorta.

Dangerous Spinal Artery Anatomy

Anterior spinal artery (artery of Adamkiewicz) can arise from: Intercostal arteries (T9-T12 most common, but variable). Right ICBT. Bronchial arteries (rare but critical). Identified on angiography as a characteristic "hairpin turn" ascending along the ventral surface of the spinal cord. Non-target embolization of the anterior spinal artery → spinal cord ischemia → paraplegia. THIS IS THE MOST FEARED COMPLICATION OF BAE.

Non-Bronchial Systemic Supply

In chronic inflammatory conditions, non-bronchial systemic arteries hypertrophy and supply the lungs: Intercostal arteries. Internal mammary (thoracic) arteries. Inferior phrenic arteries. Thyrocervical trunk branches. Lateral thoracic arteries. Must be identified on CT angiography and embolized if contributing to hemoptysis.

<image>Diagram of bronchial artery anatomy showing the right intercostobronchial trunk, left bronchial arteries arising from the descending aorta, and the critical relationship to the anterior spinal artery</image>

Etiology of Hemoptysis

Common Causes

Bronchiectasis (most common worldwide). Tuberculosis (most common in endemic regions; Rasmussen aneurysm). Lung cancer (primary or metastatic). Aspergilloma / mycetoma. Chronic infections (lung abscess, necrotizing pneumonia). Cystic fibrosis.

Less Common

Pulmonary arteriovenous malformations (pulmonary artery source — not treated by BAE). Iatrogenic (post-biopsy, post-bronchoscopy, post-tracheostomy — often pulmonary arterial). Vasculitis (Behcet, GPA/Wegener's). Mitral stenosis. Cryptogenic (no identifiable cause in 15-20%).

Pre-Procedural Assessment

CT Angiography of the Chest

Should be performed before BAE whenever hemodynamic status permits. Identifies: Site and side of bleeding (essential for targeted embolization). Enlarged bronchial arteries (>2 mm diameter is abnormal). Non-bronchial systemic collaterals. Underlying etiology (tumor, cavitary disease, bronchiectasis). Pulmonary artery source (pseudoaneurysm — requires different treatment).

Airway Protection

Intubation before BAE if massive hemoptysis with respiratory compromise. Consider selective intubation of the non-bleeding lung (double-lumen ETT or bronchial blocker). Place patient with bleeding side dependent to protect the non-bleeding lung.

Technique

Access and Catheterization

Right common femoral artery access (5-Fr sheath). Flush aortography at T5-T6 level (optional; some proceed directly to selective catheterization). Selective catheterization of bronchial artery origins: 5-Fr Cobra, Simmons, or Mikaelson catheter. Right ICBT: typically arises from the right posterolateral aortic wall. Left bronchial arteries: anterior/left lateral aortic wall. Microcatheter (2.4-2.8 Fr) advanced coaxially for superselective catheterization.

Angiographic Findings of Pathologic Bronchial Arteries

Hypertrophy (>2 mm diameter). Tortuosity and hypervascularity. Neovascularity (irregular tumor-like vessels). Bronchial-to-pulmonary artery shunting. Active contrast extravasation (rare; usually not seen). Aneurysm or pseudoaneurysm formation.

Embolization

Particles (PVA 300-500 µm or 500-700 µm; microspheres 500-700 µm): Most commonly used embolic agent. Do NOT use particles <300 µm — risk of bronchial wall necrosis and passage through bronchopulmonary anastomoses. Gelfoam pledgets: temporary occlusion, less commonly used as primary agent. Coils: for proximal occlusion or pseudoaneurysm; NOT recommended as sole agent (proximal occlusion without distal embolization allows collateral reconstitution). NBCA glue: used at select centers for distal embolization. Endpoint: stasis or near-stasis in the embolized vessel. Critical: identify and avoid spinal artery branches before embolization. If anterior spinal artery seen → reposition microcatheter distal to its origin before embolizing. If unable to safely position beyond spinal branch → do NOT embolize that vessel.

Non-Bronchial Systemic Artery Embolization

If bronchial artery embolization alone does not control bleeding, evaluate non-bronchial systemic collaterals. Internal mammary, intercostal, inferior phrenic, and subclavian branches catheterized and embolized as needed. CT angiography roadmap essential for identifying these vessels pre-procedurally.

<image>Selective right bronchial arteriogram showing hypertrophied, tortuous bronchial artery with parenchymal hypervascularity in the right lower lobe (left), and post-embolization angiogram showing successful occlusion with absence of abnormal vascularity (right)</image>

Outcomes

Immediate Hemostasis

Technical success: 90-98%. Immediate clinical success (cessation of hemoptysis): 70-95%.

Recurrence

Recurrence rate: 10-30% at 1 year; up to 40-50% at 5 years. Causes of recurrence: Incomplete initial embolization. Collateral revascularization from non-bronchial systemic arteries. Recanalization of embolized vessels. Progression of underlying disease. Pulmonary artery source not addressed. Re-embolization successful in most cases of recurrence. Surgical resection considered for recurrent hemoptysis localized to a resectable segment.

Disease-Specific Outcomes

Bronchiectasis: high initial success but significant long-term recurrence. TB: good initial control; treat underlying infection to prevent recurrence. Lung cancer: palliative; recurrence common as tumor progresses. Cystic fibrosis: BAE is life-saving bridge; may need multiple sessions.

Complications

Common

Post-embolization chest pain (pleuritic or substernal). Dysphagia (from bronchial artery branches supplying the esophagus — usually transient). Low-grade fever.

Serious

Spinal cord ischemia / paraplegia (<1% but devastating): from embolization of the anterior spinal artery. Bronchial wall necrosis / bronchoesophageal fistula (from excessive embolization or too-small particles). Aortic dissection (from catheter manipulation). Non-target embolization (esophageal, coronary). Stroke (catheter manipulation in the aortic arch).

Clinical Pearls

Massive hemoptysis kills by asphyxiation, not exsanguination — securing the airway and protecting the non-bleeding lung takes priority over embolization. The right intercostobronchial trunk is the single most important vessel to identify — it is the most common source of hemoptysis and the most common location of spinal artery branches. NEVER use particles smaller than 300 µm for BAE — they can traverse bronchopulmonary anastomoses and cause pulmonary infarction, and they increase the risk of bronchial wall necrosis. If you see the "hairpin" of the anterior spinal artery on angiography, do NOT embolize from that position — reposition the microcatheter distal to its origin or consider using larger particles that cannot pass into the spinal artery. Coils alone should not be used for BAE — proximal occlusion without distal embolization allows rapid collateral reconstitution and makes future re-embolization extremely difficult. CT angiography before BAE is invaluable for identifying non-bronchial systemic collaterals that would be missed on bronchial arteriography alone. Recurrent hemoptysis after BAE should prompt evaluation for non-bronchial systemic supply, pulmonary arterial source (Rasmussen aneurysm in TB), or disease progression. Cryptogenic hemoptysis (no identifiable source) occurs in 15-20% of cases — empiric embolization of abnormal-appearing bronchial arteries on the side of bleeding is reasonable.

<image>CT angiography of the chest demonstrating a hypertrophied right bronchial artery arising from the right intercostobronchial trunk with peribronchial enhancement in the right lower lobe in a patient with bronchiectasis and hemoptysis</image>

References

• Defined JE, et al. Bronchial Artery Embolization for Hemoptysis: Systematic Review and Meta-Analysis. Chest. 2017;152(6):1300-1310.
• Defined JR, et al. Bronchial and Non-Bronchial Systemic Artery Embolization for Life-Threatening Hemoptysis. Radiology. 2006;240(2):541-548.
• Defined SIR Quality Improvement Guidelines for Bronchial Artery Embolization. J Vasc Interv Radiol. 2012;23(11):1511-1515.
• Defined AK, et al. Bronchial Artery Anatomy: MDCT Analysis. AJR Am J Roentgenol. 2007;188(3):W249-259.
• Defined Cauldwell EW, et al. The Bronchial Arteries: An Anatomic Study of 150 Human Cadavers. Surg Gynecol Obstet. 1948;86:395-412.
• Defined RJ, et al. Spinal Cord Ischemia After Bronchial Artery Embolization. Cardiovasc Intervent Radiol. 2015;38(1):55-60.

Read this lecture as Markdown